Condition | Marginal effects | Partial effects | ||
OR (95% CI) | p-value | OR (95% CI) | p-value | |
Thyroid hormone replacement | 5.41 (2.70–12.23) | <0.001 | 6.10 (2.73–15.05) | <0.001 |
Malignancy | 1.99 (1.01–4.26) | 0.046 | 3.76 (1.47–10.43) | 0.005 |
Previous VTE | 19.36 (11.66–33.79) | <0.001 | 4.52 (2.35–9.12) | <0.001 |
Recurrent VTE | 45.02 (21.00–114.73) | <0.001 | 14.49 (5.40–43.08) | <0.001 |
Chronic venous ulcers | 3.17 (1.45–8.17) | 0.003 | 2.84 (0.99–9.00) | 0.053 |
APA/LAC | 3.28 (1.58–7.50) | 0.001 | 4.20 (1.56–12.21) | 0.004 |
Systemic lupus erythematosus | 0.06 (0.00–0.48) | 0.005 | 0.11 (0.00–1.21) | 0.076 |
VA shunt or infected pacemaker | 19.49 (2.47–2520.10) | 0.001 | 76.40 (7.67–10350.62) | <0.001 |
Inflammatory bowel disease | 2.21 (0.69–9.05) | 0.189 | 3.19 (0.74–16.03) | 0.121 |
Splenectomy | 22.09 (2.97–2824.53) | <0.001 | 17.87 (1.56–2438.07) | 0.017 |
Abnormal haemoglobins | 7.97 (0.98–1035.53) | 0.054 | 0.84 (0.05–122.42) | 0.916 |
COPD | 0.26 (0.09–0.73) | 0.012 | 0.47 (0.12–1.70) | 0.251 |
Osteomyelofibrosis | 1.47 (0.28–14.65) | 0.673 | 0.34 (0.02–8.48) | 0.519 |
CI: confidence interval; VTE: venous thromboembolism: APA/LAC: antiphospholipid antibodies/lupus anticoagulant; VA: ventriculo-atrial; COPD: chronic obstructive pulmonary disease.